US stock · Healthcare sector · Biotechnology
A
Amicus Therapeutics, Inc.
FOLD
NASDAQ12.20
USD
+0.03
(+0.25%)
Market Closed
-17.49P/E
87Forward P/E
-0.72P/E to S&P500
3.472BMarket CAP
- -Div Yield
Upcoming Earnings
2 Aug-7 Aug
Shares Short
5/15/23
21.3M
Short % of Float
7.52%
Short % of Shares Outs.
7.49%
% Held by Insiders
0.86%
% Held by Institutions
105.77%
Beta
0.81
PEG Ratio
0.16
52w. high/low
13.84/7.78
Avg. Daily Volume
2.42M
Return %
Stock
S&P 500
1 year
53.38
3.92
3 years
(6.35)
34.34
5 years
(26.44)
55.95
Scale: |
High
Low
18.00
7.16
13.50
3.21
4.84
1.88
8.12
2.10
7.29
2.47
4.27
1.90
8.79
1.76
18.83
5.69
9.83
4.41
16.60
4.95
17.62
8.27
14.62
7.11
25.39
6.25
24.84
8.60
12.96
5.91
13.84
10.55
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
0.13
0.67
2.84
0.03
0.62
0.40
0.01
0.02
- -
0.04
0.24
0.49
0.76
1.01
1.13
1.14
1.16
Earnings per share
(3.11)
(1.75)
(0.29)
(1.98)
(1.28)
(1.07)
(1.16)
(0.93)
(1.20)
(1.49)
(1.85)
(1.88)
(1.48)
(1.07)
(0.92)
(0.82)
(0.70)
FCF per share
1.10
(1.76)
(2.00)
(0.52)
(1.47)
(0.84)
(0.91)
(0.70)
(0.95)
(1.16)
(1.43)
(1.65)
(1.12)
(0.91)
(0.76)
(0.59)
(0.45)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.05
0.12
0.08
0.01
0.04
0.09
0.01
0.00
0.04
0.04
0.03
0.03
0.08
0.01
0.01
0.01
0.02
Book Value per sh.
7.80
3.16
3.18
2.34
0.86
1.52
0.89
1.64
3.16
2.68
2.30
1.85
1.98
1.11
1.13
0.43
0.46
Comm.Shares outs.
13
22
23
28
35
46
51
74
110
134
153
186
240
259
271
289
290
Avg. annual P/E ratio
(4.5)
(6.5)
(28.1)
(1.7)
(4.2)
(4.9)
(2.4)
(4.8)
(9.6)
(4.7)
(5.6)
(7.3)
(7.5)
(13.1)
(12.8)
(12.1)
(17.5)
P/E to S&P500
(0.3)
(0.3)
(0.4)
(0.1)
(0.3)
(0.3)
(0.1)
(0.3)
(0.5)
(0.2)
(0.2)
(0.3)
(0.3)
(0.3)
(0.4)
(0.6)
(0.7)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
2
15
64
1
21
18
0
1
- -
5
37
91
182
261
306
329
337
Operating margin
(2,567.5)%
(293.7)%
(11.4)%
(6,056.2)%
(237.4)%
(287.5)%
(17,680.7)%
(5,612.8)%
(Infinity)%
(3,668.6)%
(1,196.8)%
(360.3)%
(166.8)%
(94.7)%
(67.6)%
(64.4)%
(59.2)%
Depreciation (m)
1
1
2
2
2
2
2
2
2
3
4
4
5
9
6
5
10
Net profit (m)
(41)
(39)
(7)
(55)
(44)
(49)
(60)
(69)
(132)
(200)
(284)
(349)
(356)
(277)
(250)
(237)
(205)
Income tax rate
- -
- -
- -
2.0%
7.6%
6.2%
5.6%
1.6%
- -
1.8%
36.8%
0.0%
(0.1)%
(0.9)%
(3.7)%
(2.3)%
1.1%
Net profit margin
(2,307.6)%
(262.9)%
(10.2)%
(5,958.4)%
(207.2)%
(265.0)%
(16,427.8)%
(5,631.2)%
(Infinity)%
(4,034.7)%
(769.0)%
(382.5)%
(195.6)%
(106.1)%
(82.0)%
(71.9)%
(60.8)%
Working capital (m)
147
110
69
93
47
95
78
134
143
(0)
322
465
391
450
451
285
261
Long-term debt (m)
- -
- -
2
1
- -
0
14
11
42
- -
164
322
150
389
433
444
444
Equity (m)
103
71
72
65
30
69
46
122
348
360
353
343
476
286
307
123
103
ROIC
(27.2)%
(34.1)%
(8.5)%
(56.8)%
(87.6)%
(48.3)%
(50.9)%
(35.5)%
(15.6)%
68,813.8%
(49.0)%
(46.4)%
(46.8)%
(33.6)%
(28.6)%
(33.9)%
(35.0)%
Return on capital
(24.6)%
(30.6)%
(7.4)%
(49.6)%
(68.6)%
(47.2)%
(49.5)%
(32.7)%
(14.4)%
(Infinity)%
(68.9)%
(41.4)%
(39.6)%
(28.4)%
(23.1)%
(26.8)%
(28.4)%
Return on equity
(39.9)%
(55.4)%
(9.1)%
(84.6)%
(150.1)%
(70.5)%
(130.3)%
(56.4)%
(38.0)%
(55.5)%
(80.5)%
(101.8)%
(74.8)%
(96.7)%
(81.5)%
(192.3)%
(199.7)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
10 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 598
Total assets
$ 701
Long-term debt
$ 444
Cash and equiv.
$ 161
Goodwill
$ 198
Retained earnings
$ (2,585)
Common stock
291
Enterprise Value
$ 3,755
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
483
482
294
Receivables
47
53
66
Inventory
20
27
24
Other
30
117
26
Current assets
579
597
424
Acc. Payable
17
22
15
Debt due
7
7
9
Other
106
117
115
Current liabilities
130
146
139
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
7.76%
41.94%
- -
Cash flow
(17.46)%
(13.61)%
20.92%
Earnings
(5.55)%
(8.82)%
20.92%
Dividends
- -
- -
- -
Book value
(59.97)%
(13.40)%
32.98%
Insider Trading
Type
Shares
Date
Sblendorio Glenn
Exempt
15,000
05/18/23
Sblendorio Glenn
Exempt
15,000
05/18/23
Crowley John F
Sale
6,044
05/15/23
Crowley John F
Sale
6,044
05/01/23
Campbell Bradley L
Exempt
11,700
05/01/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
66
77
80
82
306
2022
79
81
82
88
329
2023
86
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.24)
(0.19)
(0.19)
(0.31)
(0.92)
2022
(0.29)
(0.22)
(0.12)
(0.19)
(0.82)
2023
(0.18)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Bradley L. Campbell M.B.A.
Full-time employees:
484
City:
Philadelphia
Address:
3675 Market Street
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Recent News